Hydroxychloroquine and Chloroquine Retinopathy Monitoring Guideline and Recommendations 2020
Hydroxychloroquine is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin.
Our range of high-quality guidance helps to maintain standards in the planning, practice and commissioning of patient care. Our clinical guidelines provide evidence-based recommendations across all aspect of care or of eye conditions; Concise Practice Points make recommendations for less frequent and targeted clinical situations, succinctly describing the scientific and clinical evidence alongside expert input to enhance clinician and patient decision making. Our Commissioning guidance supports eye units to develop services to meet local population needs.
Hydroxychloroquine is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin.
The aim of this document is to provide a framework for ophthalmic services to facilitate the administration of necessary and appropriate eye drops by unregistered health professionals to patients under the care of the ophthalmic department. It outlines how this is possible and legal within the currently legal and regulatory systems.
Covid 19 rapid advice and guidance regarding Immediate Sequential Bilateral Cataract Surgery (ISBCS) and how ISBCS can be used to limit patient's exposure to the hospital environment
A clinical tool for classification of patients with glaucoma into strata of risk for significant future sight loss and an estimate of resource requirement for managing the patient.
In this document we have developed a list of patient outcomes and associated consequence categories which aim to help guide the assessment of patient harm for ophthalmology patients
For adult patients with mental capacity to give valid consent to Cataract removal and new lens implant / Phacoemulsification and IOL
Recommended method for providers to measure delays to follow-up care using a patient administration system (PAS) field which can submit data to NHS Digital to assess national performance, provide data for managing individual patients and services, and allow reporting to commissioners and trust executive teams.
This document is to keep members informed of developments with the UK genomics services. However, this is a very fast moving area with rapid developments driven at the national level. The information in this document is correct as at February 2020.
On occasion, healthcare organisations may have concerns regarding some aspects of delivery of an ophthalmology service or they may wish to have an objective assessment of how their service is performing. Find out what the RCOphth Service Review can do for you.